Case Studies: An 80-Year-Old Man, As Well As a 62-Year-Old Man, With Metastatic Castration-Sensitive Prostate Cancer

Dan Petrylak, MD, discusses 2 case studies that focus on metastatic castration-sensitive prostate cancer, with emphasis on the use of abiraterone to treat the disease.

EP. 1: Case 1: An 80-Year-Old Man With mCSPC

January 26th 2022

Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.

EP. 2: mCSPC and the TITAN Study

January 26th 2022

Dr Petrylak recalls the study design and results of the TITAN study.

EP. 3: Unmet Needs and Key Takeaways When Treating mCSPC

January 26th 2022

An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.

EP. 4: Case 2 Introduction: A 62-Year-Old Man With mCSPC and Front-Line Approach

January 26th 2022

Dr Petrylak presents our second case, a 62-year-old man with mCSPC.

EP. 5: Using Abiraterone as a Front-Line Therapy for mCSPC and PEACE-1 Trial Details

January 26th 2022

Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.